homatropine (Homatropine (Isopto Homatropine), homatropine ophthalmic, IsoptoHomatropine)

Dosing and uses of Homatropine (Isopto Homatropine), homatropine ophthalmic (homatropine)

• Adult
• Pediatric

 

Adult dosage forms and strengths

ophthalmic solution

• 2%
• 5%

 

Cycloplegia/Mydriasis for Refraction

Discontinued by manufacturer (12/18/2012)

1-2 gtt 2% solution, or 1 gtt 5% solution, may repeat at 10-15 min intervals if necessary; not to exceed 5 doses

 

Uveitis

1-2 gtt of 2 or 5% solution in eye 2-3 times daily up to q4hr for severe uveitis

 

Pediatric dosage forms and strengths

ophthalmic solution

• 2%
• 5%

 

Cycloplegia/Mydriasis

1-2 gtt 2% solution, may repeat 10-15 min intervals if necessary; not to exceed 5 doses

 

Uveitis

1 gtt 2% solution 2-3 times daily

 

Homatropine (Isopto Homatropine), homatropine ophthalmic (homatropine) adverse (side) effects

Frequency not defined

Increased IOp

Follicular conjunctivitis

Vascular congestion

Edema

Xerostomia

Burning

Irritation

Stinging

Blurred vision

Thirst

Exudate

Eczematoid dermatitis

 

Warnings

Contraindications

Sensitivity to homatropine or components, primary glaucoma or narrow angle glaucoma

 

Cautions

Discontinue the drug if signs or symptoms of sensitivity occur during treatment or if irritation persists or increases

Use with extreme caution in infants and young children because of increased susceptibility to systemic effects

Excessive use may cause CNS adverse effects including delirium, confusion, coma, or agitation

Use appropriate eye protection (may cause sensitivity to light)

Use caution in Down syndrome patients (susceptible to angle closure glaucoma)

Use caution in patients with keratoconus; may result in fixed pupil dilation

Elderly are susceptible to side effects; use caution

Use caution in infants and young children due to susceptibility of systemic side effects

Discontinue if experiences pain within the eye

 

Pregnancy and lactation

Pregnancy category: C

Lactation: Excretion in milk unknown; not recommended

 

Pregnancy categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

 

Pharmacology of Homatropine (Isopto Homatropine), homatropine ophthalmic (homatropine)

Mechanism of action

Blocks the responses of the sphincter muscle of iris & ciliary muscle of the lens to cholinergic stimulation, thereby producing mydriasis and cycloplegia